Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients.
Van den Eynde
Eva
E
Infectious Diseases Service, Hospital Vall d'Hebron, Medicine Department, Universitat Autònoma de Barcelona, Spain.
Tiraboschi
Juan Manuel
JM
Tural
Cristina
C
Solà
Ricard
R
Mira
José Antonio
JA
Podzamczer
Daniel
D
Jou
Antoni
A
Cañete
Nuria
N
Pineda
Juan Antonio
JA
Pahissa
Albert
A
Crespo
Manuel
M
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics / Q000821:virology*; D015497:HIV-1; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage; D012367:RNA, Viral / Q000235:genetics; D011994:Recombinant Proteins; D012008:Recurrence; D012044:Regression Analysis; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a